drugset / Trial / NCT07562581
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Phase 2
Not yet recruiting
48 enrolled
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Non-randomizedSequentialOpen-labelTreatment
Summary
Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner
Timeline
- Start
- 2026-06
- Primary completion
- 2029-06
- Completion
- 2030-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 8 mg | Oral |
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Luvometinib | Small molecule | 8 mg | Oral |
| Subject | Luvometinib | Small molecule | 12 mg | Oral |